Equities

Limitless X Holdings Inc

VYBE:QBB

Limitless X Holdings Inc

Actions
  • Price (USD)0.375
  • Today's Change0.00 / 0.00%
  • Shares traded203.00
  • 1 Year change-86.11%
  • Beta-1.6007
Data delayed at least 15 minutes, as of Jun 07 2024 17:13 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Limitless X Holdings Inc. (Limitless) is a multinational consumer packaged goods company. The Company specializes in developing and offering ‘Look Good, Feel Great’ products, specifically within the nutrition and beauty industry, through direct response advertising and its brand awareness strategies. The Company operates in health products and digital marketing services. The health products sector includes the sales of health products in two primary vertical markets: health & wellness; and beauty & skincare. The digital marketing service sector includes digital marketing; digital and print design; social media marketing; and direct-to-consumer marketing. Limitless is a lifestyle brand, which is focused on the health and wellness industry. The Company has manufacturing and distribution licensing agreements to market, manufacture, sell, and distribute branded products on behalf of its clients. It plans to offer global marketing services across all areas of the sales process.

  • Revenue in USD (TTM)14.21m
  • Net income in USD-8.40m
  • Incorporated2010
  • Employees12.00
  • Location
    Limitless X Holdings Inc9454 WILSHIRE BLVD., #300BEVERLY HILLS 90212United StatesUSA
  • Phone+1 (720) 273-0433
  • Fax+1 (813) 475-7091
  • Websitehttp://www.biolabnaturals.com
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Evofem Biosciences Inc16.01m47.49m844.02k37.000.0014--0.01770.0527-5.92-5.920.0826-1.360.9351.722.73432,756.80295.02-211.64----63.65--315.54-1,031.550.0757-2.91----8.20--164.08---10.59--
Comera Life Sciences Holdings Inc1.00m-9.35m852.97k12.00------0.8526-0.4901-0.49010.05120.00330.2498--5.0883,367.50-224.98---1,094.30--73.52---900.55------0.00--97.95---237.10------
Neutra Corp17.40k-474.98k875.37k--------50.31-0.0002-0.00020.00001-0.00030.27860.4126-----758.75-682.94----46.15---2,723.22-2,758.850.0009-14.06-----26.09--22.28------
GlobeStar Therapeutics Corp0.00-1.98m930.34k-----------0.0023-0.00230.00-0.00150.00-------38,103.72-4,657.88-------7,790.20---2,834,410.00---21.00---------31.01------
Kaya Holdings Inc176.06k457.55k935.69k2.000.6622--1.855.310.06370.06370.0028-0.67060.661314.24--88,030.00186.2528.68----55.6165.75281.6566.120.0161----0.00-71.36-29.62145.01-19.45----
ENDRA Life Sciences Inc0.00-9.89m938.03k21.00--0.2509-----1.26-1.260.000.33880.00----0.00-168.89-132.00-228.29-157.28------------0.00------23.67---19.46--
Limitless X Holdings Inc14.21m-8.40m1.00m12.00------0.0705-2.10-2.103.58-3.513.731.7714.401,184,068.00-220.35------77.76---59.15--0.0173-9.02-----65.83---60.80------
Respirerx Pharmaceuticals Inc0.00-2.17m1.01m2.00---------0.014-0.0140.00-0.04120.00----0.00-2,255.78-2,491.69---------------2.90---------12.78------
Herborium Group, Inc.340.33k-318.65k1.09m2.00------3.21-0.3492-0.34920.3672-1.162.323.8925.94---216.97-490.56----58.3156.36-93.63-186.810.0331-39.14----19.45-18.15120.44------
GRI Bio Inc0.00-12.77m1.09m4.00--0.3312-----26.90-26.900.000.87530.00----0.00-382.23-192.93-869.57-353.99-------37,650.49---16.800.00-------85.61--29.46--
Himalaya Technologies Inc0.00-629.85k1.13m2.00---------0.003-0.0030.00-0.0020.00-------270.93---------------------------193.23------
Yield10 Bioscience Inc300.00k-13.15m1.18m29.00------3.94-146.30-146.301.06-123.900.0627----10,344.83-274.51-91.26-2,396.54-108.09-----4,381.67-2,279.74---------86.67-35.94-6.55--1.84--
Health Advance Inc-100.00bn-100.00bn1.19m3.00--0.3026----------0.0212----------------------------0.0356--100.00---21.75------
Vestiage Inc0.00-21.76k1.22m0.00---------0.0004-0.00040.00-0.00110.00-------4,945.46---------------------------102.30------
Sativus Tech Corp0.00-68.00k1.22m-----------0.0483-0.04830.00-0.52380.00-------18.8325.48----------------5.41------78.78------
Data as of Jun 07 2024. Currency figures normalised to Limitless X Holdings Inc's reporting currency: US Dollar USD
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.